A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

By Michael D. Green, H. Koelbl, J. Baselga, A. Galid, V. Guillem, P. Gascón, S. Siena, R. Lalisang, H. Samonigg, M. Clemens and 4 more. Annals of Oncology, 2003

617 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Oncology

View Paper: https://www.semanticscholar.org/paper/639ca2e55c6930d694d13493a69e812979022dc6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. G. Lyman
2. J. Crawford
3. D. Dale

Citations in the corpus

• Chemotherapy‐induced neutropenia (2004, background): “Grade 4 neutropenia occurred during the first cycle in 80% of patients with advanced breast carcinoma who were treated with docetaxel and doxorubicin in 2 clinical trials and declined to 40% by Cycle 4.(19,20) Those patients were given either pegfilgrastim or daily injections of filgrastim, and it a”